Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 2(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07226258Phase 3Recruiting

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

Role: lead

NCT06931262Unknown

Expanded Access Treatment Protocol With DCA for Patients With PDCD

Role: lead

NCT02616484Phase 3Active Not Recruiting

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

Role: lead

NCT05311215Phase 2Unknown

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity

Role: lead

NCT05470608Phase 2Unknown

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain

Role: lead

All 5 trials loaded